Jonathan Lim
Founder @ City Hill Ventures
San Diego, United States
Jonathan Lim is a Series B investor at City Hill Ventures in San Diego focused on Biotechnology and Therapeutics. Jonathan E. Lim is based out of San Diego, California and is the Chairman, CEO, and Co-Founder of Erasca. Jonathan previously worked at Bonti as a Chairman and Co-founder. Jonathan E. Lim attended the Harvard University.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Jonathan Lim invests in
Stages Jonathan Lim invests in
Countries Jonathan Lim invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (33%)
- Therapeutics 3 (25%)
- Life Science 2 (17%)
- Oncology 1 (8%)
- Health Care 1 (8%)
Stage
- Series B 3 (25%)
- Series A 2 (17%)
- Series C 2 (17%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $100M / Series C / May 16, 2023 | ||
| Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $190M / Venture - Series Unknown / Jan 10, 2022 | ||
| Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $105M / Series B / Apr 28, 2021 | ||
| Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations,providing patients with new potential solutions to not just treat but cure cancer.Erasca was founded in 2018 and is headquartered in San Diego, California. | $200M / Series B / Apr 27, 2020 | ||
| Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | Venture - Series Unknown / Oct 23, 2019 | ||
| Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California. | $46.4M / Series A / Sep 19, 2019 | ||
| Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations,providing patients with new potential solutions to not just treat but cure cancer.Erasca was founded in 2018 and is headquartered in San Diego, California. | $42M / Series A / Dec 18, 2018 | ||
| Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad. | $15.5M / Series C / Jan 23, 2018 | ||
| Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad. | $11.7M / Series B / Apr 19, 2017 | ||
| See all 12 investments → | |||
Co-Investors
About City Hill Ventures
City Hill Ventures, LLC is a health care focused investment firm based in San Diego, California, one of the leading metropolitan area life science clusters in the world. City Hill Ventures makes primarily seed and early stage investments in private companies in life sciences (therapeutics, diagnostics, medical devices) and health care technology.
City Hill Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Anderson
Operating Partner
|
|||
|
Jonathan Lim
Founder
|
|||
|
Karen Gilmore
Controller
|
|||
Karen Gilmore
Controller
|
|||
|
Patrick O`Connor
Operating Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jonathan Lim invest in?
Jonathan Lim invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jonathan Lim?
Public channels for Jonathan Lim include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jonathan Lim last invest?
The most recent investment recorded for Jonathan Lim closed in May 2023. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
